Virat Kohli appears able to produce miracles with his bat and the India captain masterminded yet another successful chase in Sunday’s (15) run-feast against England to enhance his reputation as the second innings king of one-day cricket.
Batting second allows a batsman to set his tempo according to demand, yet it is considered a true litmus test of stroke-making excellence due to the constant scoreboard pressure.
This was never more evident than when the opposition racked up 350 runs and reduced India to 63-4 like England did in Pune on Sunday, threatening to spoil Kohli’s first match in charge since taking over the limited-overs captaincy.
The 28-year-old replied with a sublime 122, forging a 200-run partnership with fellow centurion Kedar Jadhav, to help India chase down the steep target with 11 balls to spare.
Kohli’s ton equalled Sachin Tendulkar’s record of 17 second innings centuries, a fact made even more remarkable considering he took 136 innings fewer than the retired great, who was quick to laud the centurions on Twitter.
Former England captain Michael Vaughan was far more succinct in his assessment of the India captain, who is ranked among the top two in all three formats of the game.
“VIRAT KOHLI IS FROM ANOTHER PLANET #Fact,” Vaughan tweeted, following it with another entry in which he rated the right-hander as the top batsman in each format.
After winning the toss at the Maharashtra Cricket Association Stadium, Kohli was probably unsure what would constitute a good total at the compact venue hosting only its second one-day international.
Rather unsurprisingly he opted to field and despite cutting a frustrated figure as England bludgeoned India late in their innings, Kohli was calmness personified when his 27th one-day ton helped the hosts take a 1-0 lead in the three-match series.
This was the third time India has chased down a 350-plus target and on each occasion Kohli has struck a century.
Since his 2008 debut, India have overwhelmed targets of 300 or more on eight occasions and Kohli failed to get a century in just two of those wins.
This was also the 15th time that a Kohli ton culminated in a successful chase, more than any other batsman has managed in this format.
India’s batting mainstay averages a mind-boggling 91 in successful one-day chases but his away record is slightly less impressive.
Of his 17th second innings centuries, eight came in away matches and only four outside Asia, including one in Harare.
Having built an almost impregnable game and fuelled by an insatiable hunger for runs, Kohli is unlikely to settle for just South Asian dominance and will look to export his second innings excellence to grounds all over the world.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.